Since we started following KRYS several weeks ago its share price has gained +50%! The primary driver being positive phase 2 data for the company's lead gene therapy candidate KB103 under development as a topical treatment of Dystrophic EB (DEB), a lifelong debilitating disease. Current standards of care are only palliative, meaning they provide some relief from symptoms but do nothing to address the underlying disease pathology. DEB results from a mutation in the COL7A1 gene that makes effector proteins needed to assemble collagen. Children with the condition are called 'butterfly children' because their skin is as delicate as . . .